In view of the uncertain clinical benefit, the evidence of increased risk of serious bleeding, and its high acquisition costs, the TAU recommends that drotrecogin alfa should not be used routinely in adult patients with severe sepsis at the MUHC and CHUM. The totality of the evidence suggests that the current MUHC/CHUM policies of restricting use of this medication to those severe sepsis patients at highest risk, is most appropriate. The current clinical measures to assure optimum drug utilization should be continued. TAU also concluded that there are no current pediatric indications for drotrecogin alfa.
As with all TAU recommendations, they will be reviewed as new evidence becomes available.